ClinicalTrials.gg
Biological

13-valent pneumococcal vaccine clinical trials

Also written PCV13.

studies test it
129
open now
2
in phase 3
59
first study started
2004

How each study uses 13-valent pneumococcal vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the 13-valent pneumococcal vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
24 Feb 2010 · Prevnar 13 · BLA 125324 (FDA, Purple Book)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

13-valent pneumococcal conjugate vaccine
38
13vPnC
17
Prevnar 13
14
Prevenar13
11
Prevenar 13
11

Development codes

PCV13
28

Studies by the year they started

128 studies that test it; most in 2007 (15)

Studies that test 13-valent pneumococcal vaccine, by start year
YearStudies
20041
20051
20066
200715
20087
20095
20108
20115
20129
201315
20149
20157
20165
20177
201812
20197
20212
20223
20242
20251
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
3
Phase 1
7
Phase 2
18
Phase 3
59
Phase 4
43
No phase
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 73 · Other 56

Pfizer (35) · Wyeth is now a wholly owned subsidiary of Pfizer (22) · GlaxoSmithKline (6) · University of Oxford (5) · Korea University Guro Hospital (4) · Sanofi Pasteur, a Sanofi Company (3) · Assistance Publique - Hôpitaux de Paris (2) · Helsinki University Central Hospital (2)

Often tested with

Tested in the same studies.

23-valent pneumococcal capsular polysaccharide vaccine (8) · Pneumococcal Vaccines (7) · 10-valent pneumococcal conjugate vaccine (4) · Meningococcal Vaccines (3) · Pneumococcal 20-Valent Conjugate Vaccine (2) · Influenza Vaccines (2) · Hepatitis A Vaccines (2) · PHiD-CV vaccine (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 5 phase 3 studies under way

13-valent pneumococcal vaccine is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 1

Studies that test 13-valent pneumococcal vaccine.

Studies

Open first, then newest update. How each study uses 13-valent pneumococcal vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 129

See all 129 studies that test 13-valent pneumococcal vaccine →

Given beside what is tested · 55 — 13-valent pneumococcal vaccine is usual care or a partner of the new treatment

Showing 20 of 55.

As the comparator · 65 — what is tested is compared with 13-valent pneumococcal vaccine

Showing 20 of 65.